Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virol. Nov 25, 2022; 11(6): 467-476
Published online Nov 25, 2022. doi: 10.5501/wjv.v11.i6.467
Potential risk of liver injury in epileptic patients during COVID-19 pandemic
Nasim Tabrizi, Athena Sharifi-Razavi
Nasim Tabrizi, Athena Sharifi-Razavi, Department of Neurology, Mazandaran University of Medical Sciences, Sari 4815838477, Iran
Author contributions: Sharifi-Razavi A designed the outline, coordinated the writing of the paper and wrote first draft of manuscript; Tabrizi N searched the literature, revised first draft and wrote final manuscript.
Conflict-of-interest statement: Nasim Tabrizi and Athena Sharifi-Razavi are faculty member of Mazandaran University of Medical Sciences.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Athena Sharifi-Razavi, MD, Assistant Professor, Department of Neurology, Mazandaran University of Medical Sciences, Bou Ali Sina Hospital, Pasdaran Boulevard, Sari 4815838477, Iran.
Received: September 13, 2022
Peer-review started: September 13, 2022
First decision: September 29, 2022
Revised: October 8, 2022
Accepted: October 27, 2022
Article in press: October 27, 2022
Published online: November 25, 2022
Core Tip

Core Tip: Most of antiseizure medications (ASMs) are metabolized in liver and many of them particularly first-generation ASMs have the potential to increase liver enzymes or induce liver injury. Hence, treatment of new onset seizures or epilepsy by ASMs during the course of coronavirus disease 2019 (COVID-19), which could potentially be complicated by hepatic dysfunction, is a challenging clinical issue. In this review, we aimed to discuss the potential risks of liver injury in patients with COVID-19 who are under treatment for epilepsy or need to receive ASMs to subside acute symptomatic seizures.